ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)

Trial Details

NCT ID
NCT06182072
Phase
PHASE1
Sponsor
ProDa BioTech, LLC
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ProAgio Dose Levels (DL) 1,2,3,4
  • Gemcitabine, nab paclitaxel
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

  • Must be ≥ 18 years of age on day of signing informed consent.
  • Histologic or cytologic diagnosis of pancreatic adenocarcinoma with clinical stage IV.
  • In the dose escalation phase: patients must be eligible for gemcitabine and nab paclitaxel. For dose expansion phase: patients must have received 5…
  • Presence of a lesion that can be safely biopsied for correlative assays.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →